Treats infection caused by Orthoebolavirus zairense. Sold as Inmazeb. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Atoltivimab; Odesivimab; Maftivimab (sold as Inmazeb), first approved Oct 14, 2020, with 0 new uses approved and 0 published complete response letters.
| EBOla Post-Exposure ProphylaxisEbola Virus Disease · ANRS, Emerging Infectious Diseases | Phase 3 | Not yet recruiting | Feb 24, 2025 |
| Impact of Delay Between Administration of Inmazeb Administration and Vaccination by Ervebo on Vaccine Immune Response on Healthy VolunteersEbola Virus Disease · ANRS, Emerging Infectious Diseases | Phase 2 | Not yet recruiting | Jan 21, 2022 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Oct 14, 2020 | InmazebBLA 761169 · New molecular entity | Regeneron Pharmaceuticals | 3 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA